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Abstract
Background: The Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE) is a registered, double-blinded,
randomized, controlled trial designed to assess the efficacy of osteopathic manipulative treatment (OMT) as an
adjunctive treatment in elderly patients with pneumonia.
Methods: 406 subjects aged ≥ 50 years hospitalized with pneumonia at 7 community hospitals were randomized
using concealed allocation to conventional care only (CCO), light-touch treatment (LT), or OMT groups. All subjects
received conventional treatment for pneumonia. OMT and LT groups received group-specific protocols for 15
minutes, twice daily until discharge, cessation of antibiotics, respiratory failure, death, or withdrawal from the study.
The primary outcomes were hospital length of stay (LOS), time to clinical stability, and a symptomatic and
functional recovery score.
Results: Intention-to-treat (ITT) analysis (n = 387) found no significant differences between groups. Per-protocol
(PP) analysis (n = 318) found a significant difference between groups (P = 0.01) in LOS. Multiple comparisons
indicated a reduction in median LOS (95% confidence interval) for the OMT group (3.5 [3.2-4.0] days) versus the
CCO group (4.5 [3.9-4.9] days), but not versus the LT group (3.9 [3.5-4.8] days). Secondary outcomes of duration of
intravenous antibiotics and treatment endpoint were also significantly different between groups (P = 0.05 and
0.006, respectively). Duration of intravenous antibiotics and death or respiratory failure were lower for the OMT
group versus the CCO group, but not versus the LT group.
Conclusions: ITT analysis found no differences between groups. PP analysis found significant reductions in LOS,
duration of intravenous antibiotics, and respiratory failure or death when OMT was compared to CCO. Given the
prevalence of pneumonia, adjunctive OMT merits further study.
Background
Pneumonia is the fourth most common hospital dis-
charge diagnosis in the US with a mean (SE) length of
stay (LOS) of 5.1 (0.1) days [1]. The elderly are a vulner-
able population: the majority of pneumonia-related hos-
pital admissions occur in persons 60 years and older,
and the elderly have a longer mean LOS, higher severity
of illness, and greater mortality than younger age groups
[2-5]. Adjunctive nonpharmacologic treatments for
pneumonia may enhance conventional antibiotic
therapy. Chest physiotherapy, early mobilization, and
continuous lateral rotational therapy have been investi-
gated with mixed results [6-11]. Osteopathic manipula-
tive treatment (OMT) is a nonpharmacologic manual
therapy developed in the late nineteenth century before
the use of antibiotics. OMT includes a number of
manipulative techniques intended to enhance host
defenses and physiologic function [12-16]. Many of
these techniques, such as rib raising, doming the dia-
phragm, and the thoracic lymphatic pump, were specifi-
cally developed to treat pneumonia [15]. Two small
randomized controlled trials of OMT for pneumonia
suggest OMT may reduce LOS in the elderly [17,18].
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Elderly (MOPSE) was designed to further evaluate the
efficacy of OMT. To better understand the potential
therapeutic effect of the interaction between participants
and providers, MOPSE included sham treatment and
conventional care only control arms. The primary
hypotheses were that OMT would reduce LOS, time to
clinical stability [19], and a symptomatic and functional
recovery score [20] in elderly patients hospitalized with
pneumonia compared to light touch sham and conven-
tional care only control groups. Analysis of secondary
and safety-related outcomes was also performed.
Methods
MOPSE is a registered (http://www.clinicaltrials.gov,
NCT00258661), double-blinded, randomized, controlled
trial conducted from March 2004 to April 2007 with a
60-day post-admission follow-up period.
Subjects aged ≥ 60 years newly hospitalized with
pneumonia were recruited for MOPSE. Ten months
into the study the age criterion was lowered to ≥ 50
years to improve recruitment. Eligibility criteria included
a new pulmonary infiltrate on chest x-ray and at least
two of the following: new or increased cough, fever ≥
38°C, pleuritic chest pain, new physical findings on
chest examination, respiratory rate ≥ 25 breaths/min,
deteriorating mental or functional status, or white blood
cell count (WBC) > 12,000 cells/mm
3. Exclusion criteria
were nosocomial pneumonia, lung abscess, advancing
pulmonary fibrosis, bronchiectasis, pulmonary tubercu-
losis, lung cancer, metastatic malignancy, uncontrolled
metabolic bone diseases, current rib or vertebral frac-
ture, prior pathologic fracture, previous study participa-
tion, or respiratory failure. See Figure 1 for the MOPSE
flow diagram.
Subjects were recruited at seven community hospitals
in one rural, two suburban, and two urban US commu-
nities. The respective institutional review boards
approved the study protocol, and all participants gave
informed consent. An independent data and safety mon-
itoring board provided oversight for MOPSE.
Subjects were enrolled and randomized into three
groups: conventional care only (CCO, standard care
control), light-touch treatment (LT, sham control), or
osteopathic manipulative treatment (OMT). All subjects
received conventional treatment for pneumonia directed
by their attending physicians. Subjects were stratified by
study site and randomized from a computer-generated
list using block sizes of 3 or 6. Allocation was concealed
with opaque, sealed envelopes which were opened after
enrollment. Subjects, personnel responsible for collect-
ing data, attending physicians, nurses, and house staff
caring for subjects were blinded to group assignment.
Only the physicians giving the study treatments were
unblinded to group assignment.
Participants randomized to the OMT or LT groups
received protocol treatments for 15 minutes, twice daily
(≥ 6 hours apart) beginning within 24 hours of admis-
sion and continuing until hospital discharge, cessation
of antibiotic therapy for pneumonia, respiratory failure
(ventilator dependent), death, or study withdrawal. All
subjects were treated while supine in bed. The manipu-
lation techniques of the OMT protocol were adminis-
tered in the following sequence: thoracolumbar soft
tissue, rib raising, doming of the diaphragm myofascial
release, cervical spine soft tissue, suboccipital decom-
pression, thoracic inlet myofascial release, thoracic lym-
phatic pump, and pedal lymphatic pump [15]. Soft
tissue technique consists of massage, stretching, knead-
ing, and direct inhibitory pressure to relax the muscula-
ture. Rib raising articulates each rib for the purpose of
improving rib cage motion and theoretically stimulates
the sympathetic chain ganglia. Myofascial release is a
method for reducing tissue tension. Doming the dia-
phragm and thoracic inlet myofascial release techniques
are used to improve diaphragmatic movement and lym-
phatic drainage. Suboccipital decompression involves
traction at the base of the skull, which is considered to
release restrictions around the vagus nerves, theoreti-
cally improving nerve function. The thoracic lymphatic
pump with activation combines rhythmical compres-
sions to the chest wall and the rapid removal of the
hands from the chest wall during deep inhalation with
the intention of enhancing lymphatic circulation and
triggering a sudden expansion of airways and alveoli.
The pedal lymphatic pump gently rocks the patient in a
superior-inferior rhythmical motion while supine, to
theoretically enhance lymphatic circulation.
Non-thrust techniques were used to treat areas unad-
dressed by the above techniques, limited to ≤ 5m i n u t e s
of the 15-minute session. The LT protocol, designed as
a sham control treatment, applied light touch to the
same body regions, in the same sequence, and for the
same duration as the OMT protocol. A more detailed
description of the OMT and LT protocols has been
published [15].
Twenty osteopathic neuromusculoskeletal (OMT)
specialists and 64 resident physicians from 12 special-
ties administered the protocols. An OMT specialist at
each site administered one of the first two OMT or LT
treatments and 3 treatments per week thereafter. Using
a standardized patient, treatment skills and protocol
adherence were evaluated by the principal investigator
and an OMT specialist at 9 training sessions at each
site during the study. A pressure mapping system (Sen-
sor Products LLC, East Hanover, NJ) was used to
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Page 2 of 13Figure 1 Flow diagram of the Multicenter Osteopathic Pneumonia Study in the Elderly. ITT = intention-to-treat, PP = per-protocol, OMT =
osteopathic manipulative treatment, LT = light-touch treatment, CCO = conventional care only. Data on each site are presented in the following
order: Michigan, Missouri, New Jersey, Ohio, and Texas.
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cipital decompression, and thoracic lymphatic pump.
Presentation of the pressure mapping data is beyond
the scope of this manuscript.
Primary outcomes were LOS, time to clinical stability
[19], and a symptomatic and functional recovery score
[20]. LOS was defined by the date and time of the
admission and discharge orders. Based on data recorded
daily, time to clinical stability was defined as the hospi-
tal calendar day when all seven clinical parameters first
met criteria for stability (ie, lowest systolic blood pres-
sure ≥ 90 mmHg, highest heart rate ≤ 100 beats/min,
highest respiratory rate ≤ 24 breaths/min, highest tem-
perature ≤ 38°C, lowest oxygen saturation ≥ 90%, ability
to eat food by mouth or by a feeding tube, and mental
status back to pre-pneumonia baseline) [19]. The symp-
tomatic and functional recovery score was calculated
from a pneumonia-specific, validated questionnaire
addressing five symptoms: cough, dyspnea, sputum pro-
duction, pleuritic chest pain, and fatigue [20]. Higher
scores indicate more symptoms. This questionnaire was
administered at admission and via telephone on post-
admission days 14, 30, and 60.
Secondary outcomes were duration of intravenous and
oral antibiotics; treatment endpoint, including death and
respiratory failure; 60-day hospital readmission rate;
highest daily temperature; highest daily respiratory rate;
and WBC. Baseline severity of illness was assessed using
the pneumonia severity index [21]. Adverse events,
whether related to the study treatments or not, were
monitored daily while subjects were in the hospital.
Treatment side effects were evaluated 24 hours post-dis-
charge; subjects were asked to report the severity and
character of muscle soreness, worsening of breathing, or
other side effects. The success of subject blinding was
assessed via questionnaire within 24 hours of hospital
discharge.
Using pilot data [18] to estimate the median LOS for
the OMT and CCO groups, a log-rank test for survival
has 80% power to detect a difference in median LOS of
6 versus 9 days when the sample size in each group is
96 subjects discharged from the hospital. MOPSE was
designed to enroll 120 subjects per group with censored
values (death, respiratory failure, or study withdrawal)
estimated at ≤ 20% of the subjects.
Data were entered in duplicate at the study site and
the central coordinating center, and checked for agree-
ment. Data were analyzed by intention-to-treat (ITT)
analysis and by per-protocol (PP) analysis of subjects
receiving 100% of prescribed treatments. Data were ana-
lyzed for all subjects (≥ 50 years) and then separately for
subjects who met the original age criterion (≥ 60 years).
To test the hypotheses regarding group differences, we
used three statistical analysis methods that stratify by
study site to account for clustering. Groups were com-
pared on LOS, time to clinical stability, and duration of
in-hospital antibiotics using stratified Cox proportional
hazards models in order to include incomplete data
from subjects who withdrew from the study, died, or
were placed on a ventilator. Hazard ratios for LOS
greater than 1 correspond to earlier discharge from the
hospital for the treatment group compared to the con-
trol group. Differences in the three groups on continu-
ous outcome measures were assessed using general
linear mixed-effects models with subjects and study sites
treated as random effects and group assignment, time,
and the interaction of group and time as fixed effects.
The Cochran-Mantel-Haenszel test for general associa-
tion was used to analyze categorical outcome measures
and compare the incidence of adverse events and serious
adverse events between the groups. P values ≤ 0.05 were
considered statistically significant. The statistical ana-
lyses were performed using SAS
© version 9.1 (SAS Insti-
tute, Inc., Cary, NC).
Results
Primary and secondary outcomes
A total of 406 subjects were enrolled and randomized.
The final sample size for the ITT analysis was 387 sub-
jects; 174 males (45%), 351 Caucasian (91%), mean age
(SD) 73.7 (12.3) years. Although the selection of anti-
biotic therapy was managed by each participant’s
attending physician, 84% of subjects received antibiotic
treatment in accordance with the published practice
guidelines in place during the time of the study [22]
and 94% of subjects received antibiotic treatment in
accordance with the 2007 practice guidelines [23].
There was no significant difference between the groups
on compliance with antibiotic treatment guidelines
(P = 0.24 and 0.32, respectively). Demographic and
clinical measures, including comorbidities and pneu-
monia severity, were not significantly different between
groups (Table 1, Figures 2 and 3) with two minor
exceptions, aspiration risk (P = 0.05, LT>CCO) for
ITT analysis and current alcohol use (P = 0.03,
OMT<LT and CCO) for PP analysis.
ITT analysis found no significant difference between
the groups for any outcome (Table 2). PP analysis found
a significant difference between groups (P = 0.01) in
LOS. Multiple comparisons indicated a reduction in
median LOS (95% confidence interval [CI]) for the
OMT group (3.5 [3.2-4.0] days) versus the CCO group
(4.5 [3.9-4.9] days), but not versus the LT group (3.9
[3.5-4.8] days). There was also a significant difference
between groups (P = 0.05) in the duration of intrave-
nous antibiotics. Multiple comparisons indicated a
reduction in median duration of intravenous antibiotics
(95% CI) of 3.0 (2.7-3.5) days in the OMT group versus
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Page 4 of 133.5 (3.2-3.9) days in the CCO group. There was a signifi-
cant difference between the groups on treatment end-
point (P = 0.006). Multiple comparisons indicated the
treatment endpoints of death and respiratory failure
were less frequent in the OMT versus the CCO group.
Other outcomes were not statistically different, except
respiratory rate, which was slightly lower in the OMT
group than the CCO group (20.7 vs. 21.7 breaths/min, P
= 0.04).
Kaplan-Meier curves and hazard ratios (Figure 4) were
calculated for the ITT analysis of subjects aged ≥ 50
(ITT50+), PP analysis of subjects aged ≥ 50 (PP50+),
and PP analysis of subjects aged ≥ 60 (PP60+), who
were included for consistency with the pilot data used
in the power calculation. In Figure 4C, the PP60+ sub-
group shows significantly lower LOS in both the OMT
and LT groups relative to the CCO group (P = 0.01).
Figure 4D, comparing OMT versus LT hazard ratios,
shows no significant difference for any of the three sub-
sets. OMT shows an advantage of shortened LOS over
CCO in both PP50+ and PP60+, but not ITT50+. There
was an advantage of shortened LOS for LT over CCO
in the PP60+ analysis, but not ITT50+ or PP50+.
Safety-related outcomes
Self-reported side effects were generally mild (posttreat-
ment musculoskeletal soreness or pain) and significantly
more common in the OMT group (P = 0.003; OMT 19/
88 [22%], LT 6/86 [7%], CCO 5/76 [7%]) but resulted in
the withdrawal of only one subject. Safety-related out-
comes were determined by ITT and PP analyses (Figure
5). There were three serious adverse events in the OMT
group, causing early withdrawal; none were OMT
related per the data and safety monitoring board. PP
analysis of serious adverse events showed significant dif-
ferences between the groups on respiratory failure (P =
0.04) and death (P = 0.008). Multiple comparisons indi-
cated that respiratory failure and death were higher in
the CCO group (9/127 [7%] and 10/127 [8%], respec-
t i v e l y )c o m p a r e dt ot h eO M Tg r o u p( 1 / 9 6[ 1 % ]a n d0 /
96 [0%], respectively).
Table 1 Baseline Characteristics of the MOPSE Subjects
OMT Group
(n ITT = 130)
(n PP = 96)
LT Group
(n ITT = 124)
(n PP = 95)
CCO Group
(n ITT = 133)
(n PP = 127)
Sex - no. (%) Male
ITT Analysis 59 (45) 55 (44) 60 (45)
PP Analysis 43 (45) 39 (41) 59 (46)
Age (yrs) - mean (SD)
ITT Analysis 73.8 (11.8) 74.6 (12.5) 72.8 (12.6)
PP Analysis 74.4 (12.0) 74.9 (12.8) 72.3 (12.6)
Race - no. (%) White
ITT Analysis 122 (94) 110 (89) 119 (89)
PP Analysis 91 (95) 84 (88) 114 (90)
Body Mass Index (kg/m
2) - mean (SD)
ITT Analysis 27.6 (8.5) 27.8 (8.9) 27.4 (8.1)
PP Analysis 27.5 (7.8) 26.4 (7.3) 27.3 (8.3)
Smoking History - no. (%) Current/Former
ITT Analysis Current 25 (19) 20 (16) 34 (26)
Former 41 (32) 48 (39) 39 (29)
PP Analysis Current 18 (19) 17 (18) 32 (25)
Former 27 (28) 36 (38) 39 (31)
Current Alcohol Use by Chart Review - no. (%)
ITT Analysis 11 (9) 17 (14) 20 (15)
PP Analysis 4 (4) 14 (15) 19 (15)
Comorbidities - no. (%)
ITT Analysis COPD 51 (39) 56 (45) 59 (44)
Asthma 18 (14) 19 (15) 11 (8)
CHF 43 (33) 41 (33) 39 (29)
DM 34 (26) 33 (27) 44 (33)
HTN 83 (64) 83 (67) 83 (62)
Dementia 21 (16) 15 (12) 19 (14)
Parkinson’s 2 (2) 1 (1) 2 (2)
Stroke 19 (15) 21 (17) 18 (14)
PP Analysis COPD 36 (35) 44 (46) 57 (45)
Asthma 15 (15) 15 (16) 11 (9)
CHF 33 (32) 31 (33) 37 (28)
DM 26 (25) 24 (25) 43 (33)
HTN 68 (67) 62 (65) 80 (62)
Dementia 16 (16) 11 (12) 18 (14)
Parkinson’s 1 (1) 1 (1) 2 (2)
Stroke 15 (14) 14 (15) 17 (13)
Origin of Pneumonia - no. (%) Community-acquired (vs. Nursing
Home-acquired)
ITT Analysis 105 (81) 98 (79) 103 (77)
PP Analysis 79 (82) 75 (79) 99 (78)
Aspiration Risk by Chart Review - no. (%)
ITT Analysis 8 (6) 13 (11) 4 (3)
PP Analysis 5 (5) 8 (9) 4 (3)
Pneumonia Severity Index - no. (%)
ITT Analysis Class I-II 22 (17) 28 (23) 23 (17)
Class III 34 (26) 37 (30) 38 (29)
Class IV 52 (40) 44 (35) 53 (40)
Class V 22 (17) 15 (12) 19 (14)
Table 1: Baseline Characteristics of the MOPSE Subjects
(Continued)
PP Analysis Class I-II 18 (19) 23 (24) 23 (18)
Class III 26 (27) 27 (28) 37 (29)
Class IV 40 (42) 35 (37) 50 (39)
Class V 12 (13) 10 (11) 17 (13)
ITT = intention-to-treat, PP = per-protocol, OMT = osteopathic manipulative
treatment, LT = light-touch treatment, CCO = conventional care only, COPD =
chronic obstructive pulmonary disease, CHF = congestive heart failure, DM =
diabetes mellitus, HTN = hypertension.
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Page 5 of 13Figure 2 Comparison between intention-to-treat and per-protocol analyses on MOPSE subject comorbidities. ITT = intention-to-treat, PP
= per-protocol, OMT = osteopathic manipulative treatment, LT = light-touch treatment, CCO = conventional care only, COPD = chronic
obstructive pulmonary disease.
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Subject blinding was assessed 24 hours post-discharge.
By ITT analysis, many indicated they were “uncertain/
not sure” of their group assignment (19/88 [22%] of
OMT, 25/87 [29%] of LT, and 33/82 [40%] of CCO sub-
jects). Approximately half correctly identified their group
assignment (47/88 [53%] of OMT, 38/87 [44%] of LT,
and 40/82 [49%] of CCO subjects). For those who
believed they knew their group assignment, there was a
significant relationship between their actual and per-
ceived group assignment (P < 0.0001), with subjects more
likely to identify their group assignment correctly than to
guess they were in either of the other two groups. Of
those who believed they knew their group assignment,
more CCO subjects (40/49 [82%]) correctly identified
their group assignment than OMT (47/69 [68%]) or LT
(38/62 [61%]) subjects. PP analysis results were similar.
Discussion
By ITT analysis, OMT did not improve outcomes. By PP
analysis, OMT decreased LOS, duration of intravenous
antibiotics, and the incidence of respiratory failure and
d e a t hr e l a t i v et oC C O .T h u s ,i fas u b j e c tr e c e i v e dt h e
OMT protocol as prescribed without missing any treat-
ment sessions, there was significant benefit.
While the two studies conducted prior to MOPSE also
suggest OMT reduces LOS [17,18], the mean LOS for
all groups has been dramatically reduced since the early
1990s, from 2 weeks in the first pilot study to less than
5 days in the current study. These changes are consis-
tent with national trends [1,24,25]. The current study
was powered to detect a difference in median LOS of 6
versus 9 days, estimated using data from the single site
study [18] when the LOS was 33%-100% longer than
current standards. This LOS reduction limited the num-
ber of treatments given and the length of time to
observe the potential impact of OMT and LT on the
course of the disease. While all subjects in the current
study continued to receive antibiotic therapy after hospi-
tal discharge, study treatments ended at hospital dis-
charge. OMT may show greater efficacy when continued
beyond acute care or when used in chronic care settings.
In addition, a larger sample size may be needed to com-
pensate for the reduced LOS.
Consistent with other studies [19,26], the time to clin-
ical stability in the current study was two days, probably
too short to identify between-group differences. The
symptomatic and functional recovery score, a known
measure of long-term recovery from pneumonia [20],
did not show any between-group differences either. The
14% post-discharge loss to follow-up reduced the power
and may have lessened the ability of this measure to
detect between-group differences.
For the secondary outcome of treatment endpoint,
death and respiratory failure were reduced for OMT
relative to CCO by PP analysis. The LT group was inter-
mediate between the other two groups and not signifi-
cantly different from either. Because of the relatively low
numbers involved, these findings should be interpreted
with caution.
Significantly more patients receiving OMT experi-
enced musculoskeletal soreness or pain sometime during
Figure 3 Comparison between intention-to-treat and per-protocol analyses on MOPSE subject pneumonia severity. ITT = intention-to-
treat, PP = per-protocol, OMT = osteopathic manipulative treatment, LT = light-touch treatment, CCO = conventional care only.
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Primary Outcomes
OMT LT CCO p value
a
Hospital Length of Stay (days)
ITT Analysis (n = 130) (n = 124) (n = 133)
mean (SD) 4.5 (2.7) 4.9 (2.7) 4.5 (2.6)
median (95% CI) 3.9 (3.4-4.7) 4.5 (3.8-4.9) 4.3 (3.9-4.9) 0.53
PP Analysis (n = 96) (n = 95) (n = 127)
mean (SD) 4.0 (2.0) 4.4 (2.4) 4.5 (2.6)
median (95% CI) 3.5 (3.2-4.0) 3.9 (3.5-4.8) 4.5 (3.9-4.9) 0.01 (OMT<CCO)
Time to Clinical Stability (days)
ITT Analysis (n = 121) (n = 118) (n = 130)
mean (SD) 2.5 (1.6) 2.5 (1.4) 2.6 (1.6)
median (95% CI) 2.0 (2.0-2.0) 2.0 (2.0-3.0) 2.0 (2.0-2.0) 0.97
PP Analysis (n = 90) (n = 90) (n = 124)
mean (SD) 2.3 (1.4) 2.5 (1.5) 2.6 (1.6)
median (95% CI) 2.0 (2.0-2.0) 2.0 (2.0-2.0) 2.0 (2.0-2.0) 0.47
Symptomatic and Functional RecoveryScore
ITT Analysis - mean (SD) (n = 99) (n = 102) (n = 99)
- Admission 11.9 (4.6) 11.6 (4.4) 10.6 (4.6)
- 14-day 5.8 (4.5) 5.0 (4.0) 4.4 (3.7) Interaction (GroupxTime)
- 30-day 4.1 (4.4) 4.2 (3.6) 4.4 (3.7) p = 0.24
- 60-day 4.0 (4.7) 4.0 (4.1) 3.4 (3.6) Group p = 0.47
PP Analysis - mean (SD) (n = 80) (n = 80) (n = 91)
- Admission 11.6 (4.5) 11.6 (4.4) 10.5 (4.6)
- 14-day 5.1 (3.9) 4.6 (3.8) 4.1 (3.4) Interaction (GroupxTime)
- 30-day 3.8 (4.3) 4.0 (3.8) 4.2 (3.7) p = 0.24
- 60-day 3.6 (4.9) 3.9 (4.2) 3.2 (3.6) Group p = 0.73
Secondary Outcomes
Duration of Intravenous Antibiotic Use(days)
ITT Analysis (n = 130) (n = 124) (n = 133)
mean (SD) 3.7 (2.6) 3.9 (2.5) 3.9 (2.5)
median (95% CI) 3.3 (2.9-3.7) 3.7 (2.9-3.9) 3.5 (3.1-3.9) 0.44
PP Analysis (n = 96) (n = 95) (n = 127)
mean (SD) 3.4 (1.9) 3.7 (2.5) 3.9 (2.5)
median (95% CI) 3.0 (2.7-3.5) 3.3 (2.7-3.8) 3.5 (3.2-3.9) 0.05 (OMT<CCO)
Duration of Total (Intravenous+Oral) Antibiotic Use (days)
ITT Analysis (n = 130) (n = 124) (n = 133)
mean (SD) 4.2 (2.7) 4.6 (2.5) 4.5 (2.5)
median (95% CI) 3.6 (3.2-4.3) 4.1 (3.7-4.8) 4.0 (3.6-4.8) 0.43
PP Analysis (n = 96) (n = 95) (n = 127)
mean (SD) 4.0 (2.0) 4.4 (2.4) 4.5 (2.5)
median (95% CI) 3.5 (3.0-3.9) 3.7 (3.1-4.6) 4.0 (3.6-4.8) 0.08
Treatment Endpoint
ITT Analysis (n = 124) (n = 124) (n = 132)
n (%) Death 2 (2) 3 (3) 8 (6) 0.08
n (%) Respiratory Failure 4 (3) 4 (3) 10 (8)
n (%) Discharge 118 (95) 117 (94) 114 (86)
PP Analysis (n = 96) (n = 95) (n = 127)
n (%) Death 0 (0) 3 (3) 8 (6) 0.006
b
n (%) Respiratory Failure 1 (1) 2 (2) 9 (7)
n (%) Discharge 95 (99) 90 (95) 110 (87)
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Page 8 of 13the hospital stay. However, only one subject withdrew
consequent to this side effect, and the severity was gen-
erally mild, suggesting OMT is reasonably tolerated
even in this severely ill cohort.
Those making the clinical care decisions and collect-
ing data and the subjects were blind to group assign-
ment. The post-discharge survey suggests at least partial
blinding since only half of the participants correctly
identified their group assignment and 30% were unsure
of their group assignment. It is surprising that only 49%
of subjects in the CCO group correctly identified their
g r o u pb u tn o ts u r p r i s i n gt h a tt h o s ei nt h eC C Og r o u p
who felt certain about group assignment more consis-
tently identified their group. However, those in the
OMT and LT groups who believed they knew their
group assignment also more consistently identified their
Figure 4 Kaplan-Meier curves and hazard ratios for hospital length of stay comparing treatment groups.O M T=o s t e o p a t h i c
manipulative treatment, LT = light-touch treatment, CCO = conventional care only. A, Kaplan-Meier curves - intention-to-treat analysis on
subjects aged 50 and above. B, Kaplan-Meier curves - per-protocol analysis on subjects aged 50 and above. C, Kaplan-Meier curves - per-protocol
analysis on subjects aged 60 and above. D, Hazard ratios comparing treatment groups. Hazard ratios >1 correspond to an earlier discharge from
the hospital for the first treatment group compared to the second. Calculated using intention-to-treat analysis on subjects aged 50 and above
(ITT50+, diamond), per-protocol analysis on subjects aged 50 and above (PP50+, square), and per-protocol analysis on subjects aged 60 and
above (PP60+, triangle).
Table 2: Comparison of Treatment Groups on Primary and Secondary MOPSE Outcomes (Continued)
60-day Hospital ReadmissionRate
ITT Analysis (n = 93) (n = 96) (n = 96)
n (%) Readmission 16 (17) 20 (21) 21 (22) 0.64
PP Analysis (n = 80) (n = 79) (n = 92)
n (%) Readmission 9 (11) 16 (20) 19 (21) 0.16
ITT = intention-to-treat, PP = per-protocol, OMT = osteopathic manipulative treatment, LT = light-touch treatment, CCO = conventional care only, CI = confidence
interval.
a P values are for overall comparisons across three groups. Results from multiple comparisons are reported in parentheses.
b Death and respiratory failure were less common in the OMT group compared to the CCO group.
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Page 9 of 13group. The impact of this partial blinding should be
considered in future research.
A concern with PP analysis is that the exclusion of
subjects may compromise the baseline similarity of the
groups achieved by randomization, altering the risk-
factor profile of the subjects within the groups [27,28].
In the current study, almost 18% of subjects (26% of
OMT, 23% of LT, and 5% of CCO subjects) were
excluded from the PP analysis due to missed treat-
ments during hospitalization (43%), delayed initiation
of treatments (10%), treatment contrary to protocol
(15%), and study withdrawal (32%). As a result of these
exclusions, subjects who met PP criteria in all three
groups had significantly less severe pneumonia than
those who were excluded (P = 0.005). However, the
reasons for being excluded from PP analysis (protocol
violation, study withdrawal, or receiving less than 100%
of prescribed treatments) were not significantly related
to pneumonia severity (P = 0.77). While more subjects
were excluded from the OMT and LT groups than the
CCO group for the PP analysis, the composition of the
groups regarding demographics, comorbidities, and
pneumonia severity was not significantly different with
one minor exception for current alcohol use. This
similarity suggests that the PP analysis sustained the
between-group characteristics from the original rando-
mization, minimizing the potential bias that can occur
with PP analyses.
Another concern many have with PP analysis is
whether the results represent real world conditions.
While consistency of treatment is a valid concern and
does influence the interpretation of data, improved com-
pliance with the intended protocol can be achieved with
current quality assurance mechanisms. In the current
study, almost 70% of the subjects excluded from PP ana-
lysis were excluded for reasons that are mostly modifi-
able by healthcare providers (eg, initial treatment given
more than 24 hours after admission, incorrect treatment
given, missed treatment).
Alternatively, a concern with ITT analysis is that lack
of adherence to the treatment protocol can result in
underestimation of the impact of the treatment, particu-
larly when the proportion of subjects who did not
receive the full protocol treatment is sizable [28]. While
this concern may be valid for the current study, the
potential degree of underestimation was minimized due
to the reduced LOS, which already limited the time for
OMT efficacy.
Few studies have explored how osteopathic techniques
might enhance host defenses. In rats, rhythmic mechani-
cal pressure to body regions physically distant from the
location of lymphatic formation enhances lymph uptake
[29]. Knott et al [30] showed in a dog model that lym-
phatic pump techniques increased lymph flow through
the thoracic duct, independent of cardiac variables.
Hodge et al [31] demonstrated that abdominal
Figure 5 Analysis of adverse events comparing treatment groups. OMT = osteopathic manipulative treatment, LT = light-touch treatment,
CCO = conventional care only. Subjects may be included in more than one category. For example, three subjects had respiratory failure as their
treatment endpoint and subsequently died while still in the hospital. * Serious adverse event category excludes respiratory failure and death. A,
Intention-to-treat analysis. † OMT significantly greater than LT and CCO, P < 0.05. B, Per-protocol analysis. ‡ OMT significantly less than CCO,
P < 0.05.
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Page 10 of 13lymphatic pump in dogs increased both thoracic duct
flow and the leukocyte count in the lymph, thus increas-
ing the mobilization of immune cells. In healthy male
medical students, the lymphatic pump increased anti-
body response to pneumococcal polysaccharide [32].
However, two studies [33,34] in the elderly assessing the
lymphatic pump on antibody response to the influenza
vaccine showed no effect.
While the mechanisms are unclear, OMT may have a
beneficial effect by enhancing mobilization as has been
shown in early mobilization or kinetic bed therapy.
Immobilization is a significant mortality-predicting char-
acteristic in the elderly hospitalized with pneumonia
[35]. Early mobilization, defined as out of bed at least 20
minutes daily from day one of hospitalization, reduced
LOS in hospitalized patients with community-acquired
pneumonia [9]. In patients requiring long-term assisted
ventilation and in liver transplant recipients, kinetic or
continuous lateral rotational bed therapy reduced the
prevalence of pneumonia [8,11]. Unlike these therapies,
OMT requires little equipment and can be given to
patients unable to get out of bed.
MOPSE used a three-arm design to assess the poten-
tial therapeutic contributions of touch, attention, and
expectation associated with manual therapies. If the LT
outcomes were the same as OMT and both were better
than CCO, then the primary benefits of OMT could be
attributed to the therapeutic effect of LT. If the LT out-
comes were the same as CCO and both were inferior to
OMT, then the primary benefits of OMT could be
attributed to therapeutic benefit of OMT. However, we
found that the LT outcomes generally fell between
OMT and CCO, not significantly different from either.
T h i sm a yi n d i c a t et h a tt h ee f f e c to fO M Ti sp a r t l yd u e
to whatever is therapeutic in LT and partly due to
something inherent to OMT. One exception is the PP60
+ subgroup, where both OMT and LT had significantly
shorter LOS than CCO. It is interesting that the more
elderly subgroup would be responsive to LT. These
results highlight the need to compare the manipulative
intervention to something more than a sham control
since a two-arm study design may underestimate the
overall value of the manipulative intervention if the
sham control has some therapeutic value. The possible
therapeutic components of a sham control (such as LT)
are beyond the scope of this discussion.
MOPSE has the following limitations. The sample size
was calculated to compare the OMT and CCO groups
based on a longer LOS than the current national norm [1];
thus, the sample size may be too small to differentiate
between the OMT and control groups. Although the
MOPSE PP analysis found between-group differences, an
ITT analysis more closely reflects real world conditions.
OMT specialists administered only 3 of 8 treatments; the
rest were administered by osteopathic resident physicians
trained in the protocol. While results may improve with
administration by OMT specialists, use of non-specialists
trained in the protocol increases the generalizability of the
MOPSE results. Although regular training sessions were
conducted to standardize treatments among providers,
there are no validated objective tools to measure the qual-
ity and uniformity of each care provider’st e c h n i q u e .
Conclusions
When OMT was administered in accordance with the
protocol, reductions were seen in LOS, duration of
intravenous antibiotics, and incidence of respiratory fail-
ure and death in the OMT group compared to the CCO
group. Data suggest a reduced effect from LT compared
to OMT in that LOS for LT was between CCO and
OMT. These results suggest a potential role for OMT,
and possibly for LT, to augment conventional antibiotic
therapy in the treatment of pneumonia. This role may
become more important with increasing antibiotic resis-
tance, emerging pathogens, the aging global population,
the cost of health care, and the likelihood of another
influenza pandemic [36-38]. Since developing methods
to address these issues is a major health care imperative,
the effects of OMT and LT merit further investigation.
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